In vivo epigenetic CRISPR screen identifies Asf1a as an immunotherapeutic target in Kras-mutant lung adenocarcinoma

Despite substantial progress in lung cancer immunotherapy, the overall response rate in KRAS-mutant lung adenocarcinoma (ADC) patients remains low. Combining standard immunotherapy with adjuvant approaches that enhance adaptive immune responses—such as epigenetic modulation of anti-tumor immunity—is...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Discov
Main Authors: Li, Fei, Huang, Qingyuan, Luster, Troy A., Hu, Hai, Zhang, Hua, Ng, Wai-Lung, Khodadadi-Jamayran, Alireza, Wang, Wei, Chen, Ting, Deng, Jiehui, Ranieri, Michela, Fang, Zhaoyuan, Pyon, Val, Dowling, Catríona M., Bagdatlioglu, Ece, Almonte, Christina, Labbe, Kristen, Silver, Heather, Rabin, Alexandra R., Jani, Kandarp, Tsirigos, Aristotelis, Papagiannakopoulos, Thales, Hammerman, Peter S., Velcheti, Vamsidhar, Freeman, Gordon J., Qi, Jun, Miller, George, Wong, Kwok-Kin
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7007372/
https://ncbi.nlm.nih.gov/pubmed/31744829
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-19-0780
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados